Prostate cancer remains one of the leading causes of cancer-related deaths among men globally. In the United States, it holds the top spot as the most common cancer diagnosis among men. One of the persistent challenges in managing prostate cancer is the lack of exact biomarkers that can reliably detect early tumors.
Now, a collaboration between scientists from Sweden, the UK, and China has identified a promising set of new, precise biomarkers — found in a simple urine sample. Their groundbreaking findings, published in the journal Cancer Research, suggest that combining emerging biomedical technologies with AI could have a major impact on early cancer diagnostics, potentially far beyond just prostate cancer screening.
Early cancer diagnosis is crucial, but notoriously difficult, largely because reliable biomarkers that can be measured using routine clinical methods are still scarce. Part of the complexity lies in the biology itself: Tumors involve changes in interactions between ...
